Validation of the Sapporo criteria for antiphospholipid syndrome.
about
Gene-expression patterns predict phenotypes of immune-mediated thrombosisAssociation of beta2-glycoprotein I IgG and IgM antibodies with thrombosis and thrombocytopenia.Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.Antiphospholipid syndrome in Greece: clinical and immunological study and review of the literature.Clinical and serological follow-up of 71 patients with anti-mitochondrial type 5 antibodies.Postpartum spontaneous colonic perforation due to antiphospholipid syndromeAntiphospholipid antibodies: paradigm in transition.Moderate/severe erectile dysfunction in patients with antiphospholipid syndrome.Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients.Antiphospholipid and antioangiogenic activity in females with recurrent miscarriage and antiphospholipid syndrome.Role of investigating thrombophilic disorders in young stroke.Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosisPractice patterns of antiphospholipid syndrome at a tertiary teaching hospital in Lebanon.Antiphospholipid syndrome: an overview.Systemic lupus erythematosus and systemic autoimmune connective tissue disorders behind recurrent diastolic heart failure.Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow up.Theodore E. Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammationSome antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases.The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies.Thrombolytic therapy for cerebral vein thrombosis in antiphospholipid syndrome secondary to systemic lupus erythematosus.Antiphospholipid antibodies and pregnancy loss: a disorder of inflammationDiagnosis of antiphospholipid syndrome.Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.Plasmin immunization preferentially induces potentially prothrombotic IgG anticardiolipin antibodies in MRL/MpJ mice.Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome.Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression.The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus.The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours?Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome.International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium.Prevalence and isotype distribution of antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus (SLE).Antiphospholipid antibodies affect human endometrial angiogenesis.CSF isoelectrofocusing in a large cohort of MS and other neurological diseases.Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation.Increased risk of vascular complications in Takayasu's arteritis patients with positive lupus anticoagulant.Risk of stratified therapies for antiphospholipid antibody syndrome (APS) in pregnancy: is tailored treatment ready for prime time?An Integrated Soft Computing Approach to Hughes Syndrome Risk Assessment.Abdominal pain in patient with antiphospholipid syndrome-the role of MDCT angiography on visceral blood vessels.Catastrophic antiphospholipid syndrome with concurrent thrombotic and hemorrhagic manifestations.
P2860
Q24685918-A183242B-172C-4824-B594-C71631AE8170Q33338788-0C243931-9ED8-4FB4-8744-1D5A902063F3Q33341941-533EDAC3-21F1-4AE8-A5A5-3578893A200AQ33361734-F3D79148-E423-4891-9029-946D3E76FF16Q33376802-85ECAED7-B59B-41FD-AE5B-0C48315CBCACQ33382838-60FC3265-ADFC-4B75-BFAB-691E934244E2Q33382848-72E02C2E-4056-40B7-859E-2763F517056FQ33398166-68950B26-1B8F-43EC-B07E-AB8A29EE115EQ33410947-8989F220-646C-46B2-A0D5-956935855EF0Q33435408-D2D7A149-F81E-47ED-9ED5-CD71214CEAA2Q34573328-D2C08284-2521-48C2-8922-E02C3CF06C34Q34963070-7A2E4141-D644-44CC-B1EA-4F654AC10A04Q35021786-8F6A3C53-7AE4-492B-A58F-3259520D0A65Q35099505-3C25478A-419B-40F3-BE98-421C08AA18BBQ35224673-9B56C19D-78AB-4C16-9E56-637B6C87D327Q35555754-9B967AD3-E967-4F5A-80A2-30915A4D8D57Q35778578-D5AD3ADF-779D-483B-98C7-CCD056C6AC11Q35945526-C35EAFF6-77B3-4A56-AD64-1A293128028BQ36229639-855BA9AD-AF26-4EAA-82EB-6E1F8D42A8A2Q36314287-4D520062-584E-4B17-8DB6-C499B60DBFD7Q36468176-4F277B14-9D2F-4A0C-919A-B448DA8D7065Q36577371-BC42323D-CE26-4C77-AB0A-B3695E5826BCQ37045158-DF2F89E6-8AEC-4776-8B10-1CC01A33ABCBQ37416062-0E870AF8-4720-4335-A804-E37477F9EAEAQ37634423-0F3F7212-2993-4004-BDA8-C8D0F289BDB3Q37645693-3D23FF3B-FF6D-442F-AE50-84FD065781A4Q38125246-4E48E799-3E1F-4BA2-904E-69E9D2108AB8Q38497348-AF14CAEF-859F-43AF-911A-D2A56645283AQ39138695-C34C40EA-D5FE-44F4-9534-8A4769F0E1DCQ39716593-7953ABAF-97D4-4184-9215-8D73A7F30743Q40694046-C3788F40-2E57-447A-B12A-F76885756D63Q43677862-F8421E18-D7CF-410A-9A2B-4D18E1DE4832Q44526752-2A6E0118-B7CE-4027-B83A-082D7753B9A7Q44822871-CDEC53A9-29E3-428B-82BF-34078FD0026BQ45111033-73499426-7280-4D51-8F10-DC3AE7DDD8EFQ45779317-9EF84C51-491A-4647-B326-BB7655171387Q45880838-C80424DF-0C82-473D-8084-479372007428Q47997867-FE33D08B-4539-4A59-9A9A-E4076FE37395Q48310219-ABAF4989-C5AB-491B-B51F-BE1DE968D7A3Q50949676-3122BF74-CA6F-4DA9-9264-F36975D103E1
P2860
Validation of the Sapporo criteria for antiphospholipid syndrome.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Validation of the Sapporo criteria for antiphospholipid syndrome.
@ast
Validation of the Sapporo criteria for antiphospholipid syndrome.
@en
Validation of the Sapporo criteria for antiphospholipid syndrome.
@nl
type
label
Validation of the Sapporo criteria for antiphospholipid syndrome.
@ast
Validation of the Sapporo criteria for antiphospholipid syndrome.
@en
Validation of the Sapporo criteria for antiphospholipid syndrome.
@nl
prefLabel
Validation of the Sapporo criteria for antiphospholipid syndrome.
@ast
Validation of the Sapporo criteria for antiphospholipid syndrome.
@en
Validation of the Sapporo criteria for antiphospholipid syndrome.
@nl
P1476
Validation of the Sapporo criteria for antiphospholipid syndrome.
@en
P2093
Sammaritano LR
Schwartzman S
P304
P356
10.1002/1529-0131(200002)43:2<440::AID-ANR26>3.0.CO;2-N
P577
2000-02-01T00:00:00Z